Discovering novel chemotherapeutic drugs for the third millennium

European Journal of Cancer

Volumn 35, Issue 14, 1999, Pages 2010-2030

  Garrett, M D ^a   Workman, P ^a  

^a CRC Centre for Cancer Therapeutics   (United Kingdom)

Author keywords

Combinatorial chemistry; Contemporary drug discovery; Drug design and screening; High throughput bioscience assays; Hypothesis testing clinical trials; Molecular pharmacodynamics and imaging; Novel molecular targets; Small molecule mechanism based drugs

Indexed keywords

ANTINEOPLASTIC AGENT; CAFFEINE; CISPLATIN; CLOTRIMAZOLE; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR; DIHYDROFOLATE REDUCTASE; ENZYME INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR; FLAVOPIRIDOL; GELDANAMYCIN; GROWTH FACTOR RECEPTOR; GUANOSINE TRIPHOSPHATASE; METHYLXANTHINE DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN P55; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; PROTEINASE INHIBITOR; RADICICOL; RAS PROTEIN; RETINOBLASTOMA PROTEIN; STAUROSPORINE; TELOMERASE; TRANSFERASE INHIBITOR; TRASTUZUMAB; TYRPHOSTIN; UBIQUITIN; UNINDEXED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER; CELL CYCLE; CELL PROLIFERATION; DRUG DESIGN; DRUG DEVELOPMENT; DRUG MECHANISM; DRUG SCREENING; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW; RNA TRANSLATION; SIGNAL TRANSDUCTION;

EID: 0033402254     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(99)00280-4     Document Type: Article

References (247)

1. Baring M. From bench to bedside. Science. 278:1997;1035-1039.
2. Workman P. The potential for molecular oncology to define new drug targets. In Kerr DJ, Workman P, eds. New Molecular Targets for Cancer Chemotherapy. CRC Press Inc., 1994, 1-29.
3. Jain R.K. Delivery of novel therapeutic agents in tumors. physiological barriers and strategies J. Natl. Cancer Inst. 81:1989;570-576.
4. Stevens M.F.G. Is there a future for the small molecule in developmental cancer therapy? Waring M.J., Ponder B.A.J. The Search for New Anticancer Drugs. 1992;1-17 Kluwer, Dordrecht.
5. Workman P. Emerging molecular therapies. small molecule drugs Bronchud M.H., Foote M., Peters W.P., Robinson M.O. Principles of Molecular Oncology. 1999;413-429 Humana Press, Totowa.
6. Life in the 21st Century. A Vision for All. 1998;World Health Organisation, Geneva, Switzerland.
7. Tannock I.F. Conventional cancer therapy. promise broken or promise delayed? Lancet. 351(Suppl. II):1998;9-16.
8. Sikora K., Advani S., Koroltchouk V.et al. Essential drugs for cancer therapy. a World Health Organisation consultation Ann. Oncol. 10:1999;385-390.
9. Food and Drug Administration Web Site. http://www.fda.gov/oashi/cancer/cdrug.html.
10. Rowinsky E.K., Donehower R.C. Drug therapy. paclitaxel (Taxol) N. Engl. J. Med. 332:1995;1004-1114.
11. Cooper G.M. Oncogenes. 2nd edn. 1995;Jones and Bartlett Publishers, Boston.
12. PhRMA Web Site. http://www.phrma.org.
13. Ilyas M., Straub J., Tomlinson I.P.M., Bodmer W.F. Genetic pathways in colorectal and other cancers. Eur. J. Cancer. 35:1999;335-351.
14. Haber D.A., Fearon E.R. The promise of cancer genetics. Lancet. 351(Suppl. II):1998;1-8.
15. Lane D. The promise of molecular oncology. Lancet. 351(Suppl. II):1998;17-20.
16. Dickson D. Gene estimate rises as US and U.K. discuss freedom of access. Nature. 401:1999;311.
17. Collins F.S., Patrinos A., Jordan E., Chakravarti A., Gesteland R., Walters L. New goals for the US Human Genoma Project. 1998-2003 Science. 282:1998;682-689.
18. Drews J. Genomic sciences and the medicine of tomorrow. Nat. Biotechnol. 14:1996;1518-1519.
19. Debouck C., Goodfellow P.N. DNA microarrays in drug discovery and development. Nature Genetics. 21:1999;48-51.
20. Page M.J., Amess B., Rohlff C., Stubberfield C., Parekh R. Proteomics. a major new technology for the drug discovery process Drug Discovery Today. 4:1999;55-62.
21. Gu H., Marth J.D., Orban P.C., Mossmann H., Rajewsky K. Deletion of a DNA polymerase β gene segment in T cells using cell type-specific gene targeting. Science. 265:1994;103-106.
22. Zhang L., Zhou W., Velculescu V.E.et al. Gene expression profiles in normal and cancer cells. Science. 276:1997;1268-1272.
23. Bevan P., Ryder H., Shaw I. Identifying small-molecule lead compounds. the screening approach to drug discovery Trends in Biotechnology. 13:1995;115-121.
24. Dove A. Drug screening - beyond the bottleneck. Nature Biotech. 17:1999;859-862.
25. Archer R. The drug discovery factory. an inevitable evolutionary consequence of high-throughput parallel processing Nature Biotech. 17:1999;834.
26. Willett, ed. Computational Methods for the Analysis of Molecular Diversity. Perspectives in Drug Design. Dordrecht, Kluwer, 1997, 7/8.
27. Terrett N.K., Gardner M., Gordon D.W., Kobylecki R.J., Steele J. Combinatorial synthesis - the design of compound libraries and the application to drug discovery. Tetrahedron. 51:1995;8135-8173.
28. Hogan J.C. Combinatorial chemistry in drug discovery. Nature Biotechnology. 15:1997;328-340.
29. Rishton G.M. Reactive compounds and in vitro false positives in HTS. Drug Discovery Today. 2:1997;382-384.
30. Monks A., Scudiero D.A., Johnson G.S., Paull K.D., Sausville E.A. The NCI anti-cancer drug screen. a smart screen to identify effectors of novel targets Anticancer Drug Des. 12:1997;533-541.
31. Workman P. Towards intelligent anticancer drug screening in the post-genome era? Anti-Cancer Drug Design. 12:1997;525-531.
32. Skelton L.A., Ormerod M.G., Titley J., Kimbell R., Brunton L.A., Jackman A.L. A novel class of lipophilic quinazoline-based folic acid analogues: cytotoxic agents with a folate-independent locus. Br. J. Cancer. 79:1999;1692-1701.
33. Bradshaw T.D., Wrigley S., Shi D.F., Schultz R.J., Paull K.D., Stevens M.F. 2-(4-Aminophenyl) benzothiazoles. novel agents with selective profiles of an in vitro anti-tumour activity Br. J. Cancer. 77:1998;745-752.
34. Weinstein J., Myers T., O'Connor P.M.et al. An information-intensive approach to the molecular pharmacology of cancer. Science. 275:1997;343. For update of molecular target information see http://dtp.nci.nih.gov/ click on molecular targets.
35. Hartwell L.H., Szankasi P., Roberts C.J., Murray A.W., Friend S.H. Integrating genetic approaches into the discovery of anticancer drugs. Science. 278:1997;1064-1086.
36. Blundell T.L. Structure-based drug design. Nature. 384:1996;23-25.
37. Kubinyi H. Structure-based design of enzyme inhibitors and receptor ligands. Current Opinion in Drug Discovery and Development. 1:1998;4-15.
38. Burley S.K., Almo S.C., Bonanno J.B.et al. Structural genomics. beyond the human genome project Nature Genetics. 23:1999;151-157.
39. Crews CM, Splittgerber U. Chemical genetics: exploring and controlling cellular processes with chemical probes. TIBS 1999, 24, 317-320.
40. Eyers P.A., van den Ijssel P., Quinlan R.A., Goedert M., Cohen P. Use of a drug-resistant mutant of stress-activated protein kinase 2a/p38 to validate the in vivo specificity of SB 203580. FEBS Lett. 21:1999;191-196.
41. King F.D. Medicinal Chemistry. Principles and Practice:1994;Royal Society of Chemistry, Cambridge. 179-188.
42. Workman P. Pharmacokinetics and cancer. Successes, failures and future prospects. Workman P., Graham M.A. Pharmacokinetics and Cancer Chemotherapy. Cancer Surveys, Vol. 17. 1993;1-26 Cold Spring Harbor Laboratory Press, New York.
43. Current Drugs Drug metabolism and pharmacokinetics symposium. IF weekly highlights. Current Drugs Ltd, September 1998, 25.
44. Brown J.M., Workman P. Partition coefficient as a guide to the development of radiosensitizers which are less toxic than misonidazole. Radiat. Res. 82:1989;171-190.
45. Workman P., Brown J.M. Structure-pharmacokinetic relationships for misonidazole analogues in mice. Cancer Chemother. Pharmacol. 6:1981;39-49.
46. Rowland M. Pharmacokinetics-QSAR. definitions, concepts and models Dearden J.C. Quantitative Approaches to Drug Design. 1983;155-161 Elsevier, Amsterdam.
47. Mayer J.M., van de Waterbeemd H. Development of quantitative structure-pharmacokinetic relationships. Environmental Health Perspectives. 61:1985;295-306.
48. Blakey G.M., Nestorov I.A., Arundel P.A., Aarons L.J., Rowland M. Quantitative structure-pharmacokinetics relationships. I. Development of a whole-body physiologically based model to characterize changes in pharmacokinetics across a homologous series of barbiturates in the rat J. Pharmacokinetics and Biopharmaceutics. 25:1997;277.
49. Nestorov I., Aarons L., Rowland M. Quantitative structure-pharmacokinetics relationships. II. A mechanistically based model to evaluate the relationship between tissue distribution parameters and compound lipophilcity J. Pharmacokinetics and Biopharmaceutics. 26:1998;521.
50. Ohah T.V., McLoughlin D.A., Gilbert J.D. The simultaneous determination of mixtures of drug candidates by liquid chromatography/atmospheric pressure chemical ionization mass spectrometry as an in vivo drug screening procedure. Rapid Communications in Mass Spectrometry. 11:1997;17-23.
51. Rodrigues A.K. Preclinical drug metabolism in the age of high throughput screening. an industrial perspective Pharmaceutical Research. 14:1997;1504-1515.
52. Hollingshead M.G., Alley M.C., Camelerier R.F.et al. In vivo cultivation of tumour cells in hollow fibers. Life Sciences. 57:1995;131-141.
53. Kallman RF. Rodent Tumor Models. In Experimental Cancer Therapy. New York, Pergamon Press, 1987.
54. Gura T. Systems for identifying new drugs are often faulty. Science. 278:1997;1041-1042.
55. Kerbel R.S. What is the optimal rodent model for anti-tumor drug testing? Cancer Metastasis Rev. 17:1998;301-304.
56. Killion J.J., Radinsky R., Fidler I.J. Orthotopic models are necessary to predict therapy of transplantable tumors in mice. Cancer Metastasis Rev. 17:1998;279-284.
57. Martin D.S., Balis M.E., Fisher B.et al. Role of murine tumor models in cancer treatment research. Cancer Res. 46:1986;2189-2192.
58. Burtles S.S., Newell D.R., Henrar R.E.C., Connors T.A. Revisions of general guidelines for the preclinical toxicology of new cytotoxic anticancer agents in Europe. Eur. J. Cancer. 31A:1995;408-410.
59. Burtles S.S., Jodrell D.I., Newell D.R. Evaluation of "rodent only" preclinical toxicology for phase I trials of new cancer treatments - the Cancer Research Campaign (CRC) experience. Proc. AACR. 39:1998;363.
60. Newell D.R., Burtles S.S., Fox B.W., Jodrell D.I., Connors T.A. Evaluation of rodent-only toxicology for early clinical trials with novel cancer therapeutics. Br. J. Cancer. 81:1999;760-768.
61. Graham M.A., Kaye S.B. New approaches in preclinical and clinical pharmacokinetics. Cancer Surv. 17:1993;27-49.
62. Simon R., Freidlos B., Rubinstein L., Arbuck S.G., Collins J., Christian M.C. Accelerated titration designs for phase I trials in oncology. J. Natl. Cancer Inst. 89:1997;1138-1147.
63. Gelman K.A., Eisenhauer E.A., Harris A.L., Ratain M.J., Workman P. Anticancer agents targeting signaling molecules and cancer cell environment. challenges for drug development J. Natl. Cancer Inst. 91:1999;1281-1287.
64. Collins J.M., Zaharko D.S., Dedrick E.L.et al. Potential roles for preclinical pharmacology in phase I clinical trials. Cancer Treat. Rep. 70:1986;73-80.
65. Graham M.A., Workman P. The impact of pharmacokinetically guided dose escalation strategies in phase I clinical trials. clinical evaluation and recommendations for future studies Ann. Oncol. 3:1992;339-347.
66. O'Quigley J., Pepe M., Fisher L. Continual reassessment method. a practical design for phase I clinical trials in cancer Biometrics. 46:1990;33-48.
67. Maxwell R.J. New techniques in pharmacokinetic analysis of cancer drugs III. nuclear magnetic resonance Cancer Surv. 17:1983;415-423.
68. Tilsley D.W., Harte R.J., Jones T.et al. New techniques in the pharmacokinetic analysis of cancer drugs. IV. Positron emission tomography. Cancer Surv. 17:1993;425-442.
69. Workman P., Maxwell R.J., Griffiths J.R. Non-invasive MRS in new anticancer drug development. NMR Biomed. 5:1992;270-272.
70. Workman P. Bottlenecks in anticancer drug discovery and development. in vivo pharmacokinetic and pharmacodynamic issues and the potential role of PET Komar D. PET for Drug Development and Evaluation. 1995;277 Kluwer, Dordrecht.
71. Weissleder R. Molecular imaging. exploring the next frontier Radiology. 212:1999;609-614.
72. Pergram M.D., Lipton A., Hayes D.F.et al. Phase II study of receptor-enhanced chemosenitivity using recombinant humanised anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J. Clin. Oncol. 16:1998;2659-2671.
73. Scrip No 2374 30 September 1998, 20.
74. Slamon D.J., Godolphil W., Jones L.A.et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 244:1989;707-712.
75. Strawn L.M., Shawver L.K. Tyrosine kinases in disease. Exp. Opin. Invest. Drugs. 7:1998;553-573.
76. Levitski A., Gazit A. Tyrosine kinase inhibition. an approach to drug development Science. 267:1995;1782-1788.
77. McLeod H.L., Brunton V.G., Eckardt N.et al. In vivo pharmacology and anti-tumour evaluation of the tyrphostin tyrosine kinase inhibitor RG13022. Br. J. Cancer. 74:1996;1714-1718.
78. Fry D.W., Kraker A.J., McMichael A.et al. A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science. 265:1994;1093-1095.
79. Ward W.H.J., Cook P.N., Slater A.M., Davies D.H., Holdgate G.A., Green L.R. Epidermal growth factor receptor tyrosine kinase. Biochem. Pharmacol. 48:1994;659-666.
80. Marshall C.J. Opportunities for pharmacological intervention in the ras pathway. Ann. Oncol. 6(Suppl. 1):1995;S63-67.
81. Hancock J.F., Magee A.I., Childs J.E., Marshall C.J. All ras proteins are polyisoprenylated but only some are palmitoylated. Cell. 57:1989;1167-1177.
82. Bos J.L. The ras gene family and human carcinogenesis. Mutat. Res. 195:1988;255-271.
83. Kiaris H., Spandidos D.A. Mutations of ras genes in human tumours. Intl. J. Oncol. 7:1995;413-421.
84. Andreyev H.J., Norman A.R., Cunningham D., Oates J.R., Clarke P.A. Kirsten ras mutations in patients with colorectal cancer. the multicenter "RASCAL" study J. Natl. Cancer Inst. 90:1998;675-684.
85. Wittinghofer A., Pai E.F. The structure of Ras protein. a model for a universal switch Trends Biochem. Sci. 16:1991;382-387.
86. Hahn W.C., Counter C.M., Lundberg A.S., Bijersbergen R.L., Brooks M.W., Weinberg R.A. Creation of human tumour cells with defined genetic elements. Nature. 400:1999;464-468.
87. Chin L., Tam A., Pomerantz J.et al. Essential role for oncogenic Ras in tumour maintenance. Nature. 400:1999;468-472.
88. Mulcahy L.S., Smith M.R., Stacey D.W. Requirement for ras proto-oncogene function during serum-stimulated growth of NIH 3T3 cells. Nature. 313:1985;241-242.
89. Smith M.R., DeGuidicibus S.J., Stacey D.W. Requirement for c-ras proteins during viral oncogene transformation. Nature. 320:1986;540-543.
90. Gibbs J.B., Oliff A. Pharmaceutical research in molecular oncology. Cell. 79:1994;193-198.
91. Lerner E.C., Hamilton A.D., Sebti S.M. Inhibition of Ras prenylation. a signalling target for novel anti-cancer drug design Anti-Cancer Drug Design. 12:1997;229-238.
92. Sebti S., Hamilton A. Inhibitors of prenyl transferases. Curr. Opin. Oncol. 9:1997;557-561.
93. Stacey D.W., Feig L.A., Gibbs J.B. Dominant inhibitory Ras mutants selectively inhibit the activity of either cellular or oncogenic Ras. Mol. Cell Biol. 11:1991;4053-4064.
94. Hall-Jackson C.A., Eyers P.A., Cohen P.et al. Paradoxical activation of Raf by a novel Raf inhibitor. Chem. Biol. 6(8):1999;559-568.
95. Hall-Jackson C.A., Goedert M., Hedge P., Cohen P. Effect of SB 203580 on the activity of c-Raf in vitro and in vivo. Oncogene. 18(12):1999;2047-2054.
96. Dudley D.T., Pang L., Decker S.J., Bridges A.J., Saltiel A.R. A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc. Natl. Acad. Sci. USA. 92(17):1995;7686-7689.
97. Sebolt-Leopold J.S., Dudley D.T., Herrera R.et al. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat. Med. 5(7):1999;810-816.
98. Vanhaesebroeck B., Leevers S.J., Panayotou G., Waterfield M.D. Phosphoinositide 3-kinases. a conserved family of signal transducers Trends Biochem. Sci. 22(7):1997;267-272.
99. Khwaja A. Akt is more than just a bad kinase. Nature. 401:1999;33-34.
100. Shayesteh L., Lu Y., Kuo W.L.et al. PIK3CA is implicated as an oncogene in ovarian cancer. Nat. Genet. 21(1):1999;99-102.
101. Stambolic V., Suzuki A., de la Pompa J.L.et al. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell. 95(1):1998;29-39.
102. Vlahos C.J. Phosphatidylinositol 3-kinase inhibitors and their effects on cell signalling pathways. Drugs of the Future. 20(2):1995;165-171.
103. Cross M.J., Hodgkin M.N., Plumb J.A.et al. Inhibition of phospholipid signalling and proliferation of Swiss 3T3 cells by the wortmannin analogue demethoxyviridin. Biochim. Biophys. Acta. 1362(1):1997;29-38.
104. Schultz R.M., Merriman R.L., Andis S.L.et al. In vitro and in vivo antitumor activity of the phosphatidylinositol-3-kinase inhibitor, wortmannin. Anticancer Res. 15(4):1995;1135-1139.
105. Dierick H., Bejsovec A. Cellular mechanisms of wingless/Wnt signal transduction. Curr. Top. Dev. Biol. 43:1999;153-190.
106. Wodarz A., Nusse R. Mechanisms of Wnt signaling in development. Ann. Rev. Cell Dev. Biol. 14:1998;59-88.
107. Bullions L.C.et al. The role of beta-catenin in cell adhesion, signal transduction, and cancer. Curr. Opin. Oncol. 10(1):1998;81-87.
108. Polakis P. The oncogenic activation of beta-catenin. Curr. Opin. Genet. Dev. 9(1):1999;15-21.
109. Dierick H., Bejsovec A. Cellular mechanisms of wingless/Wnt signal transduction. Curr. Top. Dev. Biol. 43:1999;153-190.
110. Peters J.M., McKay R.M., McKay J.P., Graff J.M. Casein kinase I transduces Wnt signals. Nature. 401:1999;345-350.
111. Bienz M. APC. the plot thickens Curr. Opin. Genet. Dev. 9:1999;595-603.
112. Willert K., Shibamoto S., Nusse R. Wnt-induced dephosphorylation of axin releases beta-catenin from the axin complex. Genes Dev. 13(14):1999;1768-1773.
113. Eastman Q., Grosschedl R. Regulation of LEF-1/TCF transcription factors by Wnt and other signals. Curr. Opin. Cell Biol. 11(2):1999;233-240.
114. Nusse R, van Ooyen A, Cox D, Fung YK, Varmus H. Mode of proviral activation of a putative mammary oncogene (int-1) on mouse chromosome 15. Nature 1984, 307, 131-136.
115. Brown A.M., Wildin R.S., Prendergast T.J., Varmus H.E. A retrovirus vector expressing the putative mammary oncogene int-1 causes partial transformation of a mammary epithelial cell line. Cell. 46(7):1986;1001-1009.
116. Miyoshi Y., Nagase H., Ando H.et al. Somatic mutations of the APC gene in colorectal tumors. mutation cluster region in the APC gene Hum. Mol. Genet. 1(4):1992;229-233.
117. Rubinfeld B., Robbins P., El-Gamil M., Albert I., Porfiri E., Polakis P. Stabilization of beta-catenin by genetic defects in melanoma cell lines. Science. 275:1997;1790-1792.
118. Miyoshi Y., Iwao K., Nagasawa Y.et al. Activation of the beta-catenin gene in primary hepatocellular carcinomas by somatic alterations involving exon 3. Cancer Res. 58:1998;2524-2527.
119. Kolligs F.T., Hu G., Dang C.V., Fearon E.R. Neoplastic transformation of RK3E by mutant beta-catenin requires deregulation of Tcf/Lef transcription but not activation of c-myc expression. Mol. Cell Biol. 19:1999;5696-5706.
120. Kim K., Daniels K.J., Hay E.D. Tissue-specific expression of beta-catenin in normal mesenchyme and uveal melanomas and its effect on invasiveness. Exp. Cell Res. 245(1):1998;79-90.
121. Morgan D.O. Principles of CDK regulation. Nature. 374:1995;131-134.
122. Nasmyth K. Viewpoint. putting the cell cycle in order Science. 274:1996;1643-1645.
123. Roberts J.M. Evolving ideas about cyclins. Cell. 98(2):1999;129-132.
124. Bartkova J., Lukas J., Bartek J. Aberrations of the G1- and G1/S-regulating genes in human cancer. Prog. Cell Cycle Res. 3:1997;211-220.
125. Tsihlias J., Kapusta L., Slingerland J. The prognostic significance of altered cyclin-dependent kinase inhibitors in human cancer. Ann. Rev. Med. 50:1999;401-423.
126. Hall M., Peters G. Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer. Adv. Cancer Res. 68:1996;67-108.
127. Sherr C.J. Cancer cell cycles. Science. 274:1996;1672-1677.
128. Senderowicz A.M., Headlee D., Stinson S.F.et al. Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. Clin. Oncol. 16(9):1998;2986-2999.
129. Losiewicz M.D., Carlson B.A., Kaur G., Sausville E.A., Worland P.J. Potent inhibition of CDC2 kinase activity by the flavonoid L86-8275. Biochem. Biophys. Res. Commun. 201:1994;589-595.
130. Meijer L. Chemical inhibitors of cyclin-dependent kinases. Trends in Cell Biology. 6:1996;393-397.
131. Schnier J.B., Kaur G., Kaiser A.et al. Identification of cytosolic aldehyde dehydrogenase 1 from non-small cell lung carcinomas as a flavopiridol-binding protein. FEBS Lett. 454:1999;100-104.
132. Hooijberg J.H., Broxterman H.J., Scheffer G.L.et al. Potent interaction of flavopiridol with MRP1. Br. J. Cancer. 81:1999;269-276.
133. Hoessel R., Leclerc S., Endicott J.A.et al. Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases. Nat. Cell Biol. 1(1):1999;60-67.
134. Gray N., Detivaud L., Doerig C., Meijer L. ATP-site directed inhibitors of cyclin-dependent kinases. Curr. Med. Chem. 6(9):1999;859-875.
135. Gray N.S., Wodicka L., Thunnissen A.M.et al. Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. Science. 281:1998;533-538.
136. Chang Y.T., Gray N.S., Rosania G.R.et al. Synthesis and application of functionally diverse 2,6,9-trisubstituted purine libraries as CDK inhibitors. J. Med. Chem. 42(15):1999;2909-2919.
137. Garrett M.D., Fattaey A.C.D.K. inhibition and cancer therapy. Curr. Opin. Genet. Dev. 9:1999;104-111.
138. Nishio K., Ishida T., Arioka H.et al. Antitumor effects of butyrolactone I, a selective cdc2 kinase inhibitor, on human lung cancer cell lines. Anticancer Res. 16(6B):1996;3387-3395.
139. Yamamoto H., Monden T., Miyoshi T.et al. Cdk2/cdc2 expression in colon carcinogenesis and effects of cdk2/cdc2 inhibitor in colon cancer cells. Int. J. Oncol. 13(2):1998;233-239.
140. Schultz C., Link A., Leost M.et al. Paullones, a series of cyclin-dependent kinase inhibitors. synthesis, evaluation of CDK1/cyclin B inhibition, and in vitro antitumor activity J. Med. Chem. 42(15):1999;2909-2919.
141. Zaharevitz D.W., Gussio R., Leost M.et al. Discovery and initial characterization of the paullones, a novel class of small-molecule inhibitors of cyclin-dependent kinases. Cancer Res. 59(11):1999;2566-2569.
142. Kent L.L., Hull-Campbell N.E., Lau T., Wu J.C., Thompson S.A., Nori M. Characterization of novel inhibitors of cyclin-dependent kinases. Biochem. Biophys. Res. Commun. 260(3):1999;768-774.
143. Fahraeus R., Paramio J.M., Ball K.L., Lain S., Lane D.P. Inhibition of pRb phosphorylation and cell-cycle progression by a 20-residue peptide derived from p16CDKN2/INK4A. Curr. Biol. 6(1):1996;84-91.
144. Ball K.L., Lain S., Fahraeus R., Smythe C., Lane D.P. Cell-cycle arrest and inhibition of Cdk4 activity by small peptides based on the carboxy-terminal domain of p21WAF1. Curr. Biol. 7(1):1997;71-80.
145. Fahraeus R., Lain S., Ball K.L., Lane D.P. Characterization of the cyclin-dependent kinase inhibitory domain of the INK4 family as a model for a synthetic tumour suppressor molecule. Oncogene. 16(5):1998;587-596.
146. McConnell B.B., Starborg M., Brookes S., Peters G. Inhibitors of cyclin-dependent kinases induce features of replicative senescence in early passage human diploid fibroblasts. Curr. Biol. 8(6):1998;351-354.
147. Kato D., Miyazawa K., Ruas M.et al. Features of replicative senescence induced by direct addition of antennapedia-p16INK4A fusion protein to human diploid fibroblasts. FEBS Lett. 427(2):1998;203-208.
148. Colas P., Cohen B., Jessen T., Grishina I., McCoy J., Brent R. Genetic selection of peptide aptamers that recognize and inhibit cyclin-dependent kinase 2. Nature. 380:1996;548-550.
149. Cohen B.A., Colas P., Brent R. An artificial cell-cycle inhibitor isolated from a combinatorial library. Proc. Natl. Acad. Sci. USA. 95(24):1998;14272-14277.
150. Johnson D.G., Schneider-Broussard R. Role of E2F in cell cycle control and cancer. Front Biosci. 3:1998;d447-448.
151. Helin K., Lees J.A., Vidal M., Dyson N., Harlow E., Fattaey A.A. cDNA encoding a pRB-binding protein with properties of the transcription factor E2F. Cell. 70(2):1992;337-350.
152. Dyson N. The regulation of E2F by pRB-family proteins. Genes Dev. 12(15):1998;2245-2262.
153. Fabbrizio E., Le Cam L., Polanowska J.et al. Inhibition of mammalian cell proliferation by genetically selected peptide aptamers that functionally antagonize E2F activity. Oncogene. 18(30):1999;4357-4363.
154. Dynlacht B.D., Flores O., Lees J.A., Harlow E. Differential regulation of E2F transactivation by cyclin/cdk2 complexes. Genes Dev. 8(15):1994;1772-1786.
155. Krek W., Ewen M.E., Shirodkar S., Arany Z., Kaelin W.G. Jr., Livingston D.M. Negative regulation of the growth-promoting transcription factor E2F-1 by a stably bound cyclin A-dependent protein kinase. Cell. 78(1):1994;161-172.
156. Krek W., Xu G., Livingston D.M. Cyclin A-kinase regulation of E2F-1 DNA binding function underlies suppression of an S phase checkpoint. Cell. 83(7):1995;1149-1158.
157. Kowalik T.F., DeGregori J., Schwarz J.K., Nevins J.R. E2F1 overexpression in quiescent fibroblasts leads to induction of cellular DNA synthesis and apoptosis. J. Virol. 69(4):1995;2491-2500.
158. Qin X.Q., Livingston D.M., Kaelin W.G. Jr., Adams P.D. Deregulated transcription factor E2F-1 expression leads to S-phase entry and p53-mediated apoptosis. Proc. Natl. Acad. Sci. USA. 91(23):1994;10918-10922.
159. Chen Y.N., Sharma S.K., Ramsey T.M.et al. Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists. Proc. Natl. Acad. Sci. USA. 96(8):1999;4325-4329.
160. Lees J.A., Weinberg R.A. Tossing monkey wrenches into the clock. new ways of treating cancer Proc. Natl. Acad. Sci. USA. 96(8):1999;4221-4223.
161. Nigg E.A. Polo-like kinases. positive regulators of cell division from start to finish Curr. Opin. Cell Biol. 10(6):1998;776-783.
162. Bischoff J.R., Plowman G.D. The Aurora/Ipl1p kinase family. regulators of chromosome segregation and cytokinesis Trends Cell Biol. 9(11):1999;454-459.
163. Greenblatt M.S., Bennett W.P., Hollstein M., Harris C.C. Mutations in the p53 tumor suppressor gene. clues to cancer etiology and molecular pathogenesis Cancer Res. 54(18):1994;4855-4878.
164. Carson D.A., Lois A. Cancer progression and p53. Lancet. 346:1995;1009-1011.
165. Lane D.P. Cancer. p53, guardian of the genome. Nature. 358:1992;15-16.
166. Giaccia A.J., Kastan M.B. The complexity of p53 modulation. emerging patterns from divergent signals Genes Dev. 12(19):1998;2973-2983.
167. Prives C., Hall P.A. The p53 pathway. J. Pathol. 187(1):1999;112-126.
168. Agarwal M.L., Taylor W.R., Chernov M.V., Chernova O.B., Stark G.R. The p53 network. J. Biol. Chem. 273(1):1998;1-4.
169. Ko L.J., Prives C. p53. puzzle and paradigm Genes Dev. 10(9):1996;1054-1072.
170. Habib N.A., Hodgson H.J., Lemoine N., Pignatelli M. A phase I/II study of hepatic artery infusion with wtp53-CMV-Ad in metastatic malignant liver tumours. Hum. Gene Ther. 10(12):1999;2019-2034.
171. Clayman G.L., Frank D.K., Bruso P.A., Goepfert H. Adenovirus-mediated wild-type p53 gene transfer, as a surgical adjuvant in advanced head and neck cancers. Clin. Cancer Res. 5(7):1999;1715-1722.
172. Roth J.A., Nguyen D., Lawrence D.D.et al. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nat. Med. 2(9):1996;985-991.
173. Estreicher A., Iggo R. Retrovirus-mediated p53 gene therapy. Nat. Med. 2(11):1996;1163.
174. Selivanova G., Ryabchenko L., Jansson E., Iotsova V., Wiman K.G. Reactivation of mutant p53 through interaction of a C-terminal peptide with the core domain. Mol. Cell Biol. 19(5):1999;3395-3402.
175. Selivanova G., Kawasaki T., Ryabchenko L., Wiman K.G. Reactivation of mutant p53. a new strategy for cancer therapy Semin. Cancer Biol. 8(5):1998;369-378.
176. Wiman K.G. New p53-based anti-cancer therapeutic strategies. Med. Oncol. 15(4):1998;222-228.
177. Selivanova G., Iotsova V., Okan I.et al. Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain. Nat. Med. 3(6):1997;632-638.
178. Prives C. Signaling to p53. breaking the MDM2-p53 circuit Cell. 95(1):1998;5-8.
179. Picksley S.M., Vojtesek B., Sparks A., Lane D.P. Immunochemical analysis of the interaction of p53 with MDM2;- fine mapping of the MDM2 binding site on p53 using synthetic peptides. Oncogene. 9(9):1994;2523-2529.
180. Bottger V., Bottger A., Howard S.F.et al. Identification of novel mdm2 binding peptides by phage display identification of novel mdm2 binding peptides by phage display. Oncogene. 13(10):1996;2141-2147.
181. Bottger A., Bottger V., Sparks A., Liu W.L., Howard S.F., Lane D.P. Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo. Curr. Biol. 7(11):1997;860-869.
182. Lain S., Midgley C., Sparks A., Lane E.B., Lane D.P. An inhibitor of nuclear export activates the p53 response and induces the localization of HDM2 and p53 to U1A-positive nuclear bodies associated with the PODs. Exp. Cell Res. 248(2):1999;457-472.
183. Bischoff J.R., Kirn D.H., Williams A.et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science. 274:1996;373-376.
184. Kirn D., Hermiston T., McCormick F. ONYX-015. clinical data are encouraging Nat. Med. 4(12):1998;1341-1342.
185. O'Connor P.M. Mammalian G1 and G2 phase checkpoints. Cancer Surv. 29:1997;151-182.
186. O'Connor P.M., Fan S. DNA damage checkpoints. implications for cancer therapy Prog. Cell Cycle Res. 2:1996;165-173.
187. Wang Q., Fan S., Eastman A., Worland P.J., Sausville E.A., O'Connor P.M. UCN-01. a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53 J. Natl. Cancer Inst. 88(14):1996;956-965.
188. Yu L., Orlandi L., Wang P.et al. UCN-01 abrogates G2 arrest through a Cdc2-dependent pathway that is associated with inactivation of the Wee1Hu kinase and activation of the Cdc25C phosphatase. J. Biol. Chem. 273(50):1998;33455-33464.
189. Sausville E.A., Lush R.D., Headlee D.et al. Clinical pharmacology of UCN-01. initial observations and comparison to preclinical models Cancer Chemother. Pharmacol. 42(Suppl.):1998;S54-59.
190. Komarov P.G., Komarova E.A., Kondratov R.V.et al. A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science. 285:1999;1733-1737.
191. Conlon I., Raff M. Size control in animal development. Cell. 96(2):1999;235-244.
192. Leevers S.J. All Creatures Great and Small. Science. 285:1999;2082-2083.
193. Brooks R.F. Continuous protein synthesis is required to maintain the probability of entry into S phase. Cell. 12(1):1977;311-317.
194. Sonenberg N. Translation factors as effectors of cell growth and tumorigenesis. Curr. Opin. Cell Biol. 5(6):1993;955-960.
195. Clemens M.J., Bommer U.A. Translational control. the cancer connection Int. J. Biochem. Cell Biol. 31(1):1999;1-23.
196. Sonenberg N., Gingras A.C. The mRNA 5′ cap-binding protein eIF4E and control of cell growth. Curr. Opin. Cell Biol. 10(2):1998;268-275.
197. Jagus R., Joshi B., Barber G.N. PKR apoptosis and cancer. Int. J. Biochem. Cell Biol. 31(1):1999;123-138.
198. Willis A.E. Translational control of growth factor and proto-oncogene expression. Int. J. Biochem. Cell Biol. 31(1):1999;73-86.
199. Dever T.E. Translation initiation. adept at adapting Trends Biochem. Sci. 24(10):1999;398-403.
200. Aktas H., Fluckiger R., Acosta J.A., Savage J.M., Palakurthi S.S., Halperin J.A. Depletion of intracellular Ca2+ stores, phosphorylation of eIF2alpha, and sustained inhibition of translation initiation mediate the anticancer effects of clotrimazole. Proc. Natl. Acad. Sci. USA. 95(14):1998;8280-8285.
201. McKendrick L., Pain V.M., Morley S.J. Translation initiation factor 4E. Int. J. Biochem. Cell Biol. 31(1):1999;31-35.
202. Keiper B.D., Gan W., Rhoads R.E. Protein synthesis initiation factor 4G. Int. J. Biochem. Cell Biol. 31(1):1999;37-41.
203. Raught B., Gingras A.C. eIF4E activity is regulated at multiple levels. Int. J. Biochem. Cell Biol. 31(1):1999;43-57.
204. Rhoads R.E. Signal transduction pathways that regulate eukaryotic protein synthesis. J. Biol. Chem. 274(43):1999;30337-30340.
205. Gingras A.C., Gygi S.P., Raught B.et al. Regulation of 4E-BP1 phosphorylation. a novel two-step mechanism Genes Dev. 13(11):1999;1422-1437.
206. Minich W.B., Balasta M.L., Goss D.J., Rhoads R.E. Chromatographic resolution of in vivo phosphorylated and nonphosphorylated eukaryotic translation initiation factor eIF-4E. increased cap affinity of the phosphorylated form Proc. Natl. Acad. Sci. USA. 91(16):1994;7668-7672.
207. Pyronnet S., Imataka H., Gingras A.C., Fukunaga R., Hunter T., Sonenberg N. Human eukaryotic translation initiation factor 4G (eIF4G) recruits mnk1 to phosphorylate eIF4E. EMBO J. 18(1):1999;270-279.
208. Brattstrom C., Tyden G., Sawe J., Herlenius G., Claesson K., Groth C.G. A randomized, double-blind, placebo-controlled study to determine safety, tolerance, and preliminary pharmacokinetics of ascending single doses of orally administered sirolimus (rapamycin) in stable renal transplant recipients. Transplant Proc. 28(2):1996;985-986.
209. Hosoi H., Dilling M.B., Shikata T.et al. Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cells. Cancer Res. 59(4):1999;886-894.
210. Ciechanover A. The ubiquitin-proteasome pathway. on protein death and cell life EMBO J. 17(24):1998;7151-7160.
211. Hershko A., Ciechanover A. The ubiquitin system. Ann. Rev. Biochem. 67:1998;425-479.
212. Spataro V., Norbury C., Harris A.L. The ubiquitin-proteasome pathway in cancer. Br. J. Cancer. 77(3):1998;448-455.
213. Schwartz A.L., Ciechanover A. The ubiquitin-proteasome pathway and pathogenesis of human diseases. Ann. Rev. Med. 50:1999;57-74.
214. Jarrousse A.S., Gautier K., Apcher S.et al. Relationships between proteasomes and viral gene products. Mol. Biol. Rep. 26(1-2):1999;113-117.
215. Scheffner M., Huibregtse J.M., Vierstra R.D., Howley P.M. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell. 75(3):1993;495-505.
216. Steeg P.S., Abrams J.S. Cancer prognostics. past, present and p27 Nat. Med. 3(2):1997;152-154.
217. Porter P.L., Malone K.E., Heagerty P.J.et al. Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat. Med. 3(2):1997;222-225.
218. Catzavelos C., Bhattacharya N., Ung Y.C.et al. Decreased levels of the cell-cycle inhibitor p27Kip1 protein. prognostic implications in primary breast cancer Nat. Med. 3(2):1997;227-230.
219. Loda M., Cukor B., Tam S.W.et al. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat. Med. 3(2):1997;231-234.
220. Foo S.Y., Nolan G.P. NF-kappaB to the rescue. RELs, apoptosis and cellular transformation Trends Genet. 15(6):1999;229-235.
221. Chu Z.L., McKinsey T.A., Liu L., Gentry J.J., Malim M.H., Ballard D.W. Suppression of tumor necrosis factor-induced cell death by inhibitor of apoptosis c-IAP2 is under NF-kappaB control. Proc. Natl. Acad. Sci. USA. 94(19):1997;10057-10062.
222. Sharma H.W., Narayanan R. The NF-kappaB transcription factor in oncogenesis. Anticancer Res. 16(2):1996;589-596.
223. Fenteany G., Schreiber S.L. Lactacystin, proteasome function, and cell fate. J. Biol. Chem. 273(15):1998;8545-8548.
224. Isoe T., Naito M., Shirai A., Hirai R., Tsuruo T. Inhibition of different steps of the ubiquitin system by cisplatin and aclarubicin. Biochim. Biophys. Acta. 1117(2):1992;131-135.
225. Lee D.H., Goldberg A. Proteasome inhibitors. valuable new tools for cell biologists Trends Cell Biol. 8(10):1998;397-403.
226. Adams J., Palombella V.J., Sausville E.A.et al. Proteasome inhibitors. a novel class of potent and effective antitumor agents Cancer Res. 59(11):1999;2615-2622.
227. Patton E.E., Willems A.R., Tyers M. Combinatorial control in ubiquitin dependent proteolysis. don't Skp the F-box hypothesis Trends Genet. 14(6):1998;236-243.
228. Lisztwan J., Imbert G., Wirbelauer C., Gstaiger M., Krek W. The von Hippel-Lindau tumor suppressor protein is a component of an E3 ubiquitin-protein ligase activity. Genes Dev. 13(14):1999;1822-1833.
229. Sheaff R.J., Groudine M., Gordon M., Roberts J.M., Clurman B.E. Cyclin E-CDK2 is a regulator of p27Kip1. Genes Dev. 11(11):1997;1464-1478.
230. Luo R.X., Dean D.C. Chromatin remodelling and transcriptional regulation. J. Natl. Cancer Inst. 91(15):1999;1288-1294.
231. Kouzarides T. Histone acetylases and deacetylases in cell proliferation. Curr. Opin. Genet. Dev. 9(1):1999;40-48.
232. Saito A., Yamashita T., Mariko Y.et al. A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc. Natl. Acad. Sci. USA. 96(8):1999;4592-4597.
233. Mayer M.P., Bukau B. Molecular chaperones. the busy life of Hsp90 Curr. Biol. 9(9):1999;R322-325.
234. Schulte T.W., Neckers L.M. The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin. Cancer Chemother. Pharmacol. 42(4):1998;273-279.
235. Kelland L.R., Sharp S.Y., Rogers P.M., Myers T.G., Workman P. DT-diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90. J. Natl. Cancer Inst. 91(22):1999;1-10.
236. Dolan M.E., Pegg A.E. O6-benzylguanine and its role in chemotherapy. Clin. Cancer Res. 3(6):1997;837-847.
237. Griffin R.J., Crutin N.J., Newell D.R., Golding B.T., Durkacz B.W., Calvert A.H. The role of inhibitors of poly(ADP-ribose) polymerase as resistance-modifying agents in cancer therapy. Biochimie. 77(6):1995;408-422.
238. Jackson S.P. DNA damage detection by DNA dependent protein kinase and related enzymes. Cancer Surv. 28:1996;261-279.
239. Hahn W.C., Stewart S.A., Brooks M.W.et al. Inhibition of telomerase limits the growth of human cancer cells. Nat. Med. 5(10):1999;1164-1170.
240. Zumstein L.A., Lundbald V. Telomeres. has cancer's Achilles' heel been exposed? Nat. Med. 5(10):1999;1129-1130.
241. De Lange T., Jacks T. For better or worse? Telomerase inhibition and cancer. Cell. 98(3):1999;273-275.
242. Perry P.J., Kelland L.R. Telomeres and telomerase. targets for cancer chemotherapy Exp. Opin. Ther. Patents. 8(12):1998;1567-1586.
243. Drews J. In Quest of Tomorrow's Medicines. New York, Springer-Verlag, 1999.
244. Yu L., Graves P, Tempcyzk A., Sausville E.A., Piwnica-Worms H., O'Connor P.M. The checkpoint kinase Chk1 is a target of the anticancer agent UCN-01. Proc. AACR. 40:1999;304.
245. De Benedetti A., Harris A.L. EIF4E expression in tumours. its possible role in progression of malignancies Int. J. Biochem. Cell Biol. 31(1):1999;59-72.
246. Pharmaprojects, Richmond, PJB Publications, 1999.
247. Le Coutre P., Mologni L., Cleris L.et al. In vivo eradication of human bcr/abl-positive leukemia cells with an abl kinase inhibitor. J. Natl. Cancer Inst. 91(2):1999;163-168.